ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.
Grzegorz S NowakowskiAnnalisa ChiappellaRandy D GascoyneDavid W ScottQingyuan ZhangWojciech JurczakMuhit ÖzcanXiaonan HongJun ZhuJie JinDavid BeladaJuan-Miguel BerguaFrancesco A PiazzaHeidi MócikovaAnna Lia MolinariDok Hyun YoonFederica CavalloMonica TaniKazuhito YamamotoKoji IzutsuKoji KatoMyron CzuczmanSarah HerseyAdrian KilcoyneJacqueline RussoKrista HudakJingshan ZhangSteve WadeThomas E WitzigUmberto VitoloPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
ROBUST is the first DLBCL phase III study to integrate biomarker-driven identification of eligible ABC patients. Although the ROBUST trial did not meet the primary end point of PFS in all patients, the safety profile of R2-CHOP was consistent with individual treatments with no new safety signals.